Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical's revenue rose 20.2% to $673 million in fiscal 2025. Its operating margin was −79.5%, up from −95.7% a year earlier. Free cash flow was −$472 million. The diluted share count rose 8.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Ultragenyx Pharmaceutical does
Ultragenyx is a drug company that develops and sells treatments for rare and ultra-rare genetic diseases, many of which have no approved therapy that treats the underlying cause. It uses several kinds of medicine: biologics (made from living cells), small molecules, gene therapy that uses a harmless virus to deliver genes, and nucleic acid drugs.
It earns money from its approved products. They include Crysvita, an antibody for X-linked hypophosphatemia (a bone disease) and a related tumor-linked condition, which it develops and sells together with Kyowa Kirin, and Mepsevii, an enzyme therapy for a very rare disorder called MPS VII. It also has Evkeeza, an antibody for a rare inherited form of high cholesterol, which its partner Regeneron markets in the United States. The company mostly licenses its drug candidates from universities or other drug makers and aims to keep worldwide selling rights.
It has its own sales teams in North America, Europe, the United Kingdom, Latin America, Türkiye and Asia, and uses distributors in smaller markets. Alongside its sold products it runs a set of clinical-stage programs, which are medicines still being tested in people.
Its biggest risks, as it describes them
- It depends on Kyowa Kirin for the development, supply and sale of Crysvita, one of its main products.
- Its drug candidates can fail in later trials even after promising early results, or be delayed.
- Regulators may not approve its candidates, or may approve them for narrower uses than it wants.
- It has a limited operating history and may need to raise more money.
- Making gene therapies and other complex medicines is difficult, and it relies on outside makers.
Income statement
Ultragenyx Pharmaceutical lost money in fiscal 2025: a net loss of $575 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 740 | 748 | 578 | 610 | 680 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 4.7x | 3.4x | 2.6x | 2.4x | 2.5x |
| Quick ratio | 4.6x | 3.3x | 2.5x | 2.2x | 2.3x |
Cash flow
Projections
Project Ultragenyx Pharmaceutical's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Ultragenyx Pharmaceutical says to expect
- Full year 2026: total revenue
The company reaffirms its full year 2026 total revenue guidance of $730 million to $760 million, which excludes revenue from new product launches.
- Full year 2026: Crysvita revenue
The company reaffirms its full year 2026 Crysvita revenue guidance of $500 million to $520 million.
- Full year 2026: Dojolvi revenue
The company reaffirms its full year 2026 Dojolvi revenue guidance of $100 million to $110 million.
- Full year 2027: R&D and SG&A expenses
To support this transition, the company has initiated substantial headcount and expense reductions and expects to reduce 2027 R&D expenses to less than $350 million and 2027 SG&A expenses to less than $375 million.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Ultragenyx Pharmaceutical shares on the open market, and 9 insiders sold $3.7 million, $1.3 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Theodore Alan HuizengaSVP, Chief Accounting Officer | Sold plan | 1,283 | $13.57 | $17,410 | Form 4 |
| Sep 3, 2026 | Theodore Alan HuizengaSVP, Chief Accounting Officer | Sold | 161 | $13.99 | $2,252 | Form 4 |
| Aug 3, 2026 | Howard HornChief Financial Officer | Sold plan | 4,696 | $24.92 | $117,024 | Form 4 |
| Aug 3, 2026 | Karah Herdman ParschauerEVP and Chief Legal Officer | Sold plan | 1,900 | $24.92 | $47,348 | Form 4 |
| Jul 1, 2026 | Howard HornChief Financial Officer | Sold plan | 4,698 | $33.13 | $155,645 | Form 4 |
| Jun 15, 2026 | Corazon (Corsee) D. SandersDirector | Sold | 2,000 | $25.05 | $50,100 | Form 4 |
| Jun 15, 2026 | Karah Herdman ParschauerEVP and Chief Legal Officer | Sold plan | 1,899 | $24.62 | $46,753 | Form 4 |
| Jun 1, 2026 | Howard HornChief Financial Officer | Sold plan | 4,653 | $23.77 | $110,602 | Form 4 |
| May 18, 2026 | Shehnaaz SulimanDirector | Sold plan | 5,740 | $25.12 | $144,189 | Form 4 |
| May 5, 2026 | Eric CrombezEVP and Chief Medical Officer | Sold | 344 | $24.96 | $8,586 | Form 4 |
| May 1, 2026 | Howard HornChief Financial Officer | Sold plan | 4,683 | $24.90 | $116,607 | Form 4 |
| Apr 1, 2026 | Howard HornChief Financial Officer | Sold plan | 4,683 | $20.97 | $98,203 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −100.1% | −46.1% | −50.0% |
| Altman Z'' | −7.75 | −8.70 | −9.61 |
| Accruals ratio | −8.7% | −10.3% | −7.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put Ultragenyx Pharmaceutical side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical | FY25 | 20.2% | −79.5% | −70.1% | — | — | — | |
| Kiniksa Pharmaceuticals | FY25 | 60.1% | 11.4% | 20.1% | — | — | — | Compare |
| Amphstar Pharmaceuticals | FY25 | −1.6% | 19.5% | 16.8% | 9.9% | 1.7x | 6 | Compare |
| Pacira BioSciences | FY25 | 3.6% | 2.6% | 18.8% | 1.1% | 1.2x | 9 | Compare |
| OPKO Health | FY25 | −14.9% | −19.4% | −31.4% | −7.0% | — | 4 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | 3 | 52 | 104 | 271 | 351 | 363 | 434 | 560 | 673 |
| Revenue growth | — | 1,863.9% | 1,871.5% | 101.4% | 161.3% | 29.7% | 3.4% | 19.4% | 29.0% | 20.2% |
| Gross profit | — | 3 | 50 | — | — | — | — | — | — | — |
| Research and development | 183 | 232 | 294 | 357 | 412 | 497 | 706 | 648 | 698 | 750 |
| Operating income | −248 | −329 | −371 | −424 | −330 | −382 | −649 | −569 | −536 | −535 |
| Net income | −246 | −302 | −198 | −403 | −187 | −454 | −707 | −607 | −569 | −575 |
| Diluted EPS (US$) | −6.21 | −7.12 | −3.97 | −7.12 | −3.07 | −6.70 | −10.12 | −8.25 | −6.29 | −5.83 |
| Diluted shares (millions) | 40 | 42 | 50 | 57 | 61 | 68 | 70 | 74 | 90 | 99 |
| Cash flow | ||||||||||
| Cash from operations | −161 | −254 | −291 | −345 | −132 | −339 | −380 | −475 | −414 | −466 |
| Capital expenditure | 10 | 3 | 4 | 25 | 44 | 73 | 116 | 44 | 7 | 6 |
| Free cash flow | −171 | −257 | −295 | −370 | −176 | −412 | −497 | −519 | −421 | −472 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 143 | 0 | 0 | 0 | 0 | 75 | 0 | 0 | 0 |
| Stock-based compensation | 48 | 68 | 80 | 82 | 86 | 105 | 130 | 135 | 158 | 153 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 380 | 234 | 460 | 755 | 1,202 | 740 | 748 | 578 | 610 | 680 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 541 | 491 | 720 | 1,136 | 1,760 | 1,522 | 1,545 | 1,491 | 1,503 | 1,532 |
| Total liabilities | 67 | 107 | 111 | 482 | 605 | 600 | 1,193 | 1,216 | 1,241 | 1,605 |
| Shareholders' equity | 474 | 384 | 609 | 654 | 1,154 | 923 | 352 | 275 | 255 | −80 |
| Margins and ratios | ||||||||||
| Gross margin | — | 100.0% | 97.8% | — | — | — | — | — | — | — |
| Operating margin | −186,471.4% | −12,593.5% | −721.2% | −409.0% | −121.8% | −108.6% | −178.6% | −131.1% | −95.7% | −79.5% |
| Net margin | −184,867.7% | −11,567.3% | −383.8% | −388.3% | −68.8% | −129.2% | −194.7% | −139.9% | −101.6% | −85.4% |
| Free cash flow margin | −128,694.0% | −9,825.3% | −572.2% | −357.0% | −65.0% | −117.2% | −136.7% | −119.6% | −75.2% | −70.1% |
| Rule of 40 (growth + FCF margin) | — | −7,961.4% | 1,299.3% | −255.6% | 96.3% | −87.5% | −133.3% | −100.1% | −46.1% | −50.0% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −48.9% | −70.5% | −39.8% | −63.8% | −20.6% | −43.7% | −111.0% | −193.6% | −214.7% | −657.1% |
| Return on assets | −44.7% | −58.6% | −32.6% | −43.4% | −12.9% | −27.7% | −46.1% | −40.0% | −38.0% | −37.9% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |